OCGN Stock Risk & Deep Value Analysis

Ocugen remains a highly speculative, binary investment centered on OCU400, its gene-agnostic therapy for inherited retinal diseases. Since the last analysis, no new material clinical data has been released, leaving the efficacy of OCU400 as the primary unknown. The previously noted operational de-risking (full enrollment, interim safety) and extended cash runway (now approximately 10-13 months) are still relevant, providing time for trial completion. However, the high cash burn persists, and without definitive efficacy, future dilutive financing is highly probable. The 10x potential is solely dependent on OCU400's success in Phase 3 and subsequent commercialization, which still faces significant clinical and financial hurdles, slightly tempered by the passage of time without further de-risking news.